CiteFacts · FDA Drug Shortages · FDA source
FDA shortage status: Streptozocin Powder, For Solution
FDA source answer
FDA currently lists this ingredient in shortage.
FDA source statuses: Current. First FDA posting: 2022-07-12. Latest FDA row update: 2026-10-01.
FDA lists 2 package records, with companies: ESTEVE PHARMACEUTICALS, S.A., Teva Pharmaceuticals USA, Inc.. Package NDCs: 0703-4636-01, 68118-100-01.
FDA shortage reason: Other
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Package NDC | Presentation | FDA availability field | FDA update |
|---|---|---|---|---|
| ESTEVE PHARMACEUTICALS, S.A. | 68118-100-01 | Zanosar, Powder, For Solution, 1 g/10 mL (NDC 68118-100-01) | Available | 2026-09-16 |
| Teva Pharmaceuticals USA, Inc. | 0703-4636-01 | Zanosar, Powder, For Solution, 100 mg/1 mL (NDC 0703-4636-01) | Unavailable | 2026-10-01 |
Source facts
Grouped generic ingredient: Streptozocin Powder, For Solution · 2 package records
Therapeutic categories: Oncology
Dosage forms: Powder, For Solution
Routes: Not stated
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-10-06T18:55:41+00:00. Derived grouping is documented in this record's derivations.